<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-23768" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Iron Dextran</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Failla</surname>
            <given-names>Sebastiano</given-names>
          </name>
          <aff>Nova Southeastern University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Nicolas</surname>
            <given-names>Samar</given-names>
          </name>
          <aff>MCPHS University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Parmar</surname>
            <given-names>Mayur</given-names>
          </name>
          <aff>Nova Southeastern University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sebastiano Failla declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Samar Nicolas declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mayur Parmar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>15</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-23768.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Iron dextran is an injectable complex comprising&#x000a0;ferric hydroxide and a low-molecular-weight fraction of dextran.&#x000a0;Iron dextran is an intravenous iron solution tailored to treat iron deficiency anemia.&#x000a0;Oral iron therapy is frequently used for the treatment of iron deficiency anemia. However, certain patients either exhibit inadequate responses to oral iron or encounter difficulties in its administration. Iron dextran has been approved by&#x000a0;the US Food and Drug Administration (FDA) for treating iron deficiency anemia in patients who are unresponsive to oral iron therapy or cannot tolerate it.</p>
        <p>Injectable iron proves particularly beneficial in cases of iron deficiency stemming from conditions such as excessive iron loss (eg, hereditary hemorrhagic telangiectasia and significant blood loss) or iron malabsorption (eg, Crohn disease, celiac disease, inflammatory bowel disease, and gastric bypass).&#x000a0;The appropriate application of iron dextran is recommended for iron deficiency anemia associated with menometrorrhagia, pregnancy, and surgical blood loss. This activity is tailored for healthcare professionals and summarizes indications, mechanisms of action, pharmacokinetics, administration protocols, and potential adverse effects associated with iron dextran therapy, emphasizing&#x000a0;the pivotal role of an interprofessional healthcare team in optimizing patient outcomes while utilizing iron dextran. In addition, this&#x000a0;activity highlights algorithms for making informed decisions in the clinical management of patients undergoing iron dextran treatment by&#x000a0;providing insights into contraindications, monitoring strategies, and potential overdose risks of iron dextran.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify appropriate candidates for iron dextran therapy based on their response to oral iron therapy,&#x000a0;clinical indications, and iron deficiency anemia severity.</p></list-item><list-item><p>Screen patients for conditions that may benefit from iron dextran therapy, including those with excessive iron loss or malabsorption syndromes.</p></list-item><list-item><p>Assess patients for contraindications and potential adverse effects associated with iron dextran therapy, ensuring timely intervention if complications arise.</p></list-item><list-item><p>Collaborate with other healthcare professionals to optimize patient outcomes through coordinated care and shared decision-making.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23768&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23768">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-23768.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Oral iron therapy is frequently used for the treatment of iron deficiency anemia. However, certain patients either exhibit inadequate responses to oral iron or encounter difficulties in its administration.<xref ref-type="bibr" rid="article-23768.r1">[1]</xref> Iron dextran is an injectable complex comprising&#x000a0;ferric hydroxide and a low-molecular-weight fraction of dextran.<xref ref-type="bibr" rid="article-23768.r2">[2]</xref>&#x000a0;Iron dextran is an intravenous (IV) iron solution for treating iron deficiency anemia.</p>
        <p>Injectable iron proves particularly beneficial in cases of iron deficiency stemming from conditions such as excessive iron loss (eg, hereditary hemorrhagic telangiectasia and significant blood loss) or iron malabsorption (eg, Crohn disease, celiac disease, inflammatory bowel disease, and gastric bypass).&#x000a0;The&#x000a0;appropriate application of iron dextran is recommended for iron deficiency anemia associated with menometrorrhagia, pregnancy, and surgical blood loss.<xref ref-type="bibr" rid="article-23768.r3">[3]</xref></p>
        <p>
<bold>FDA-Approved Indication</bold>
</p>
        <p>Iron dextran has&#x000a0;been approved by&#x000a0;the US Food and Drug&#x000a0;Administration&#x000a0;(FDA) for treating iron deficiency anemia in patients&#x000a0;who are unresponsive to oral iron therapy or cannot tolerate it.<xref ref-type="bibr" rid="article-23768.r1">[1]</xref><xref ref-type="bibr" rid="article-23768.r4">[4]</xref></p>
        <p>
<bold>Off-Label Use</bold>
</p>
        <p>Iron dextran is sometimes utilized off-label for restless leg syndrome (RLS). However, as per the RLS guidelines, there is insufficient evidence to determine the safety and efficacy of iron dextran for treating RLS.<xref ref-type="bibr" rid="article-23768.r5">[5]</xref></p>
      </sec>
      <sec id="article-23768.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>After administering iron dextran, macrophages remove iron dextran from the bloodstream into the reticuloendothelial system (RES) via endocytosis.<xref ref-type="bibr" rid="article-23768.r6">[6]</xref><xref ref-type="bibr" rid="article-23768.r7">[7]</xref> The RES separates the components of iron dextran.<xref ref-type="bibr" rid="article-23768.r8">[8]</xref> Iron binds to transferrin, an iron-binding protein that transports iron to the bone marrow.<xref ref-type="bibr" rid="article-23768.r9">[9]</xref> The iron-transferrin complex binds to transferrin receptor 1 (TFR1) expressed on erythroid progenitor cells, and iron dissociates from transferrin.<xref ref-type="bibr" rid="article-23768.r10">[10]</xref> Erythroid progenitor cells use iron to produce heme, a component of hemoglobin.<xref ref-type="bibr" rid="article-23768.r11">[11]</xref> In the presence of erythropoietin, erythroid progenitor cells mature into erythrocytes.<xref ref-type="bibr" rid="article-23768.r12">[12]</xref> Hemoglobin is a component of the mature erythrocytes that transport oxygen in the body. Red blood cell count increases about&#x000a0;7 days after iron dextran infusion.<xref ref-type="bibr" rid="article-23768.r1">[1]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p>Iron dextran is a prodrug in the form of an iron carbohydrate complex.<xref ref-type="bibr" rid="article-23768.r13">[13]</xref> Dextran is the carbohydrate component bound to iron and resembles a ferritin-iron complex.<xref ref-type="bibr" rid="article-23768.r14">[14]</xref> Ferritin is an antigenic protein administered IV. Therefore, iron dextran is manufactured by replacing ferritin with a carbohydrate, rendering it a non-antigenic compound.<xref ref-type="bibr" rid="article-23768.r14">[14]</xref></p>
        <p><bold>Absorption:</bold> The absorption of iron dextran after intramuscular (IM) administration may take up to 3 weeks. Reticulocyte count peaks 5 to 10 days after iron dextran administration, and hemoglobin increases in 2 to 4 weeks.<xref ref-type="bibr" rid="article-23768.r13">[13]</xref></p>
        <p><bold>Distribution:</bold> Transferrin transports iron to the bone marrow for red blood cell production. The liver stores most of the excess iron in the form of ferritin or hemosiderin.<xref ref-type="bibr" rid="article-23768.r15">[15]</xref></p>
        <p><bold>Metabolism:</bold> The dextran component is degraded and excreted in the urine.<xref ref-type="bibr" rid="article-23768.r16">[16]</xref> Iron is not actively excreted from the body.<xref ref-type="bibr" rid="article-23768.r15">[15]</xref> Iron released from red blood cell destruction is recycled to form new red blood cells. Therefore, long-term iron infusions may result in iron accumulation in organs.</p>
        <p><bold>Elimination:</bold> Iron dextran has a dose-dependent half-life of 1 day to 3.5 days.<xref ref-type="bibr" rid="article-23768.r13">[13]</xref> Since iron is continuously recycled in the body, the half-life does not represent elimination. This half-life represents the time until phagocytes take iron dextran from the plasma.<xref ref-type="bibr" rid="article-23768.r17">[17]</xref></p>
      </sec>
      <sec id="article-23768.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths</bold>
</p>
        <p>Currently,&#x000a0;2 forms of low-molecular-weight iron dextran are available in the North American market. Both&#x000a0;are injectable solutions&#x02014;IV or IM&#x02014;containing 50 mg/mL of elemental iron.<xref ref-type="bibr" rid="article-23768.r2">[2]</xref><xref ref-type="bibr" rid="article-23768.r14">[14]</xref> Idiosyncratic reactions to iron dextran, such as hypotension and anaphylaxis, are not dose-dependent.<xref ref-type="bibr" rid="article-23768.r18">[18]</xref> Therefore, an initial one-time 25 mg test dose of iron dextran is necessary before commencing iron dextran therapy for adults and children with a body weight of over 20 kg.</p>
        <p>For children with a body weight of less than 10 kg, the test dose is 10 mg, whereas for children with a body weight of 10 to 20 kg, the test dose is 15 mg. After administering the test dose, healthcare professionals should monitor&#x000a0;patients for 1 hour before administering the therapeutic dose. Anaphylactic reactions to therapeutic doses&#x000a0;are observed in patients who tolerated the iron dextran test dose. Emergency medications should be readily accessible&#x000a0;if the patient experiences an anaphylactic reaction.</p>
        <p>IM&#x000a0;injections&#x000a0;are administered to the upper outer quadrant of the buttock using the Z-track technique, which involves laterally displacing the skin before injection.</p>
        <p>
<bold>Adult Dosage</bold>
</p>
        <p>The manufacturer recommends against exceeding 2 mL of iron dextran per day. If the calculated dose exceeds 2 mL, then daily doses of 2 mL or less should be administered until the total calculated dose is reached.&#x000a0;</p>
        <p><bold>Iron deficiency anemia dosing:&#x000a0;</bold>According to the manufacturer, iron dextran dose is weight-based when treating iron deficiency anemia. The lean body weight (LBW) should be used in the formula unless the actual body weight is less than LBW. If the actual body weight is less than the LBW, then the actual body weight should be used.&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Iron dextran's weight-based formula for iron deficiency anemia for adults and children with a body weight of more than 15 kg is:</p>
          </list-item>
        </list>
        <p>Total dose (in mL) = 0.0442 (Desired hemoglobin &#x02013; observed hemoglobin) x LBW + (0.26 x LBW)</p>
        <list list-type="bullet">
          <list-item>
            <p>Iron dextran's weight-based formula for iron deficiency anemia for children with a body weight of 5 to 15 kg is:</p>
          </list-item>
        </list>
        <p>Total dose (in mL) = 0.0442 (Desired hemoglobin &#x02013; observed hemoglobin) x Weight + (0.26 x Weight)</p>
        <p>Hemoglobin is in grams/deciliter (g/dL), and LBW or body weight is in kilograms (kg).</p>
        <p><bold>Iron replacement for blood loss dosing:&#x000a0;</bold>According to the manufacturer, the total dose for iron replacement due to blood loss can be calculated as follows:</p>
        <p>Total dose (in mL) = [blood loss (in mL) x hematocrit]/50 mg/mL</p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Renal impairment:&#x000a0;</bold>Iron dextran does not require renal dosage adjustment.</p>
        <p><bold>Hepatic impairment:&#x000a0;</bold>Iron dextran does not require hepatic dosage adjustment.</p>
        <p><bold>Pregnancy considerations:&#x000a0;</bold>The American College of Obstetrics and Gynecology (ACOG) recommends oral iron as a first-line therapy for iron deficiency anemia during pregnancy.<xref ref-type="bibr" rid="article-23768.r19">[19]</xref> IV iron may be used in patients who cannot tolerate or do not respond to oral iron. Data about the safety of IV iron during the first trimester is lacking. Iron dextran can be used during the second and third trimesters of pregnancy.<xref ref-type="bibr" rid="article-23768.r20">[20]</xref></p>
        <p><bold>Breastfeeding&#x000a0;considerations:&#x000a0;</bold>The World Health Organization (WHO) considers iron dextran compatible with breastfeeding.</p>
      </sec>
      <sec id="article-23768.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Although iron dextran&#x000a0;is historically correlated with significant rates of adverse drug events, a retrospective review demonstrated that most events were associated with the high-molecular-weight formulation of iron dextran, which&#x000a0;is withdrawn from the US market.<xref ref-type="bibr" rid="article-23768.r21">[21]</xref> A patient with a history of multiple drug allergies has a higher risk of allergy to iron dextran.<xref ref-type="bibr" rid="article-23768.r22">[22]</xref> Most literature reports adverse effects for all&#x000a0;IV iron preparations and are not agent-specific.<xref ref-type="bibr" rid="article-23768.r23">[23]</xref><xref ref-type="bibr" rid="article-23768.r24">[24]</xref></p>
        <p>The risk of infusion reactions and anaphylaxis varies by the rate of administration, dose, and stability of the IV iron formulation.<xref ref-type="bibr" rid="article-23768.r25">[25]</xref> Infusion reaction, known as complement activation-related pseudoallergy (CARPA), is a major adverse event for all IV iron.<xref ref-type="bibr" rid="article-23768.r24">[24]</xref> Labile iron does not bind quickly to transferrin, increasing CARPA risk.<xref ref-type="bibr" rid="article-23768.r25">[25]</xref> CARPA is not life-threatening. Symptoms of CARPA include flushing, myalgias, arthralgias, back pain, and chest pressure.<xref ref-type="bibr" rid="article-23768.r25">[25]</xref> Interrupting the infusion and restarting slower usually resolves mild infusion reactions.<xref ref-type="bibr" rid="article-23768.r24">[24]</xref> More severe acute reactions with iron dextran are uncommon and include dyspnea, hypotension, chest pain, angioedema, neurological symptoms, and urticaria.<xref ref-type="bibr" rid="article-23768.r18">[18]</xref><xref ref-type="bibr" rid="article-23768.r26">[26]</xref>&#x000a0;Fluids and steroids help manage moderate infusion reactions.<xref ref-type="bibr" rid="article-23768.r24">[24]</xref> IM epinephrine and oxygen help manage severe reactions.<xref ref-type="bibr" rid="article-23768.r27">[27]</xref> Antihistamines may worsen hypersensitivity reactions.</p>
        <p>The currently available iron dextran is low-molecular-weight and carries a box warning for increased risk of anaphylaxis.<xref ref-type="bibr" rid="article-23768.r28">[28]</xref><xref ref-type="bibr" rid="article-23768.r29">[29]</xref> However, data to support the belief that low-molecular-weight iron dextran has the highest risk of anaphylaxis among injectable iron formulations is controversial.<xref ref-type="bibr" rid="article-23768.r28">[28]</xref>&#x000a0;A study showed that 2-hour infusions of 400 to 500 mg of iron sucrose had higher infusion-related side effects than iron dextran or lower-dose iron sucrose.<xref ref-type="bibr" rid="article-23768.r28">[28]</xref> Therefore, patients requiring a high dose of iron need to receive the total dose of iron sucrose over multiple visits.</p>
        <p>A commentary in the Kidney International Journal supports using low-molecular-weight dextran over iron sucrose when the patient requires a high dose of iron.<xref ref-type="bibr" rid="article-23768.r28">[28]</xref> According to the National Kidney Foundation, patients can receive up to 1,000 mg of iron dextrose as a single dose, allowing the administration of a total dose infusion (TDI) in one visit.<xref ref-type="bibr" rid="article-23768.r28">[28]</xref><xref ref-type="bibr" rid="article-23768.r30">[30]</xref><xref ref-type="bibr" rid="article-23768.r18">[18]</xref> The TDI is not FDA-approved because of the associated delayed dose-related arthralgias and myalgias.<xref ref-type="bibr" rid="article-23768.r28">[28]</xref><xref ref-type="bibr" rid="article-23768.r18">[18]</xref></p>
        <p>Although IV iron&#x000a0;is thought to increase the risk of infections, a systematic review and meta-analysis showed no increased infection risk with IV iron formulations.<xref ref-type="bibr" rid="article-23768.r31">[31]</xref><xref ref-type="bibr" rid="article-23768.r32">[32]</xref> In addition, IV iron causes fewer gastrointestinal adverse events than oral iron.<xref ref-type="bibr" rid="article-23768.r24">[24]</xref>&#x000a0;</p>
        <p>
<bold>Drug-Drug Interactions</bold>
<italic toggle="yes"/>
</p>
        <p>Angiotensin-converting enzyme inhibitors decrease the breakdown of kinins and may increase the risk of anaphylaxis when administered with iron dextran.<xref ref-type="bibr" rid="article-23768.r33">[33]</xref><xref ref-type="bibr" rid="article-23768.r33">[33]</xref><xref ref-type="bibr" rid="article-23768.r33">[33]</xref></p>
        <p>Dimercaprol binds to iron, forming a nephrotoxic complex. Coadministration of dimercaprol with iron dextran is not recommended.</p>
      </sec>
      <sec id="article-23768.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>
<bold>Warnings and Precautions</bold>
</p>
        <p>The Kidney Disease Improving Global Outcomes (KDIGO) guidelines recommend against using IV iron in patients with systemic infections.<xref ref-type="bibr" rid="article-23768.r34">[34]</xref> IV iron increases the risk of infections because IV iron increases non-transferrin-bound iron, making free iron readily available to promote pathogen replication.<xref ref-type="bibr" rid="article-23768.r35">[35]</xref></p>
        <p>IV iron is contraindicated in the first trimester of pregnancy because studies confirming its safety in the first trimester are lacking.<xref ref-type="bibr" rid="article-23768.r36">[36]</xref>&#x000a0; Factors that increase the likelihood of hypersensitivity reactions to IV iron are relative contraindications to all IV iron preparations and are not specific to iron dextran. The European Medicine Agency (EMA) identifies the rationale for the relative contraindications of IV iron.<xref ref-type="bibr" rid="article-23768.r36">[36]</xref>&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Factors that increase the incidence and severity of hypersensitivity reactions include previous reactions to IV iron, fast infusion rate, or mastocytosis.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Factors that worsen the outcome of hypersensitivity reactions include severe respiratory or cardiac disease, elderly, beta-blockers, or&#x000a0;angiotensin-converting enzyme&#x000a0;inhibitors.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Factors that increase the risk of hypersensitivity reactions include the history of allergy to other drugs, patient anxiety, or anxiety of staff administering the drug.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23768.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Vital signs and skin reactions are safety monitoring parameters.<xref ref-type="bibr" rid="article-23768.r37">[37]</xref> The healthcare team should measure vital signs at baseline and monitor vital signs and skin reactions for 1 hour after administering a 25 mg (0.5 mL) test dose. Vital signs and skin reactions should also be monitored during and after therapeutic doses. As for efficacy, anemia-related parameters should be monitored, including hemoglobin, hematocrit, reticulocyte count, serum ferritin, serum iron, total iron-binding capacity (TIBC), and transferrin saturation.<xref ref-type="bibr" rid="article-23768.r38">[38]</xref></p>
      </sec>
      <sec id="article-23768.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Transferrin is a protein that transports soluble, nontoxic iron in the body.<xref ref-type="bibr" rid="article-23768.r39">[39]</xref> Transferrin saturation (TSAT) is a biomarker that indicates iron status. TSAT &#x0003c;20% suggests iron deficiency, and TSAT &#x0003e;40% indicates iron overload.<xref ref-type="bibr" rid="article-23768.r40">[40]</xref> Free iron accumulates in the liver when TSAT reaches 60% to 70%. Free iron is toxic as it changes rapidly between divalent and trivalent forms, leading to chemical reactions and the production of oxygen radicals. This results in cellular, molecular, and organ damage.</p>
        <p>Signs and symptoms of iron overload include nausea, vomiting, diarrhea, metabolic acidosis, hypotension, hepatic failure, and death.<xref ref-type="bibr" rid="article-23768.r41">[41]</xref> The risk of iron overload increases when chronic administration of IV iron exceeds the amount of blood loss.<xref ref-type="bibr" rid="article-23768.r42">[42]</xref><xref ref-type="bibr" rid="article-23768.r43">[43]</xref>&#x000a0;Iron chelating agents bind to iron accumulated in organs.<xref ref-type="bibr" rid="article-23768.r44">[44]</xref> Iron bound to the chelator is excreted in the urine and feces. Iron chelators include IV or IM deferoxamine, oral deferiprone, and oral deferasirox.</p>
      </sec>
      <sec id="article-23768.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Comprehensive knowledge, training, and collaboration among all interprofessional team members are essential for ensuring patient safety while administering iron dextran preparations. Clinicians must thoroughly evaluate the suitability of parenteral iron, including iron dextran. Pharmacists play a crucial role in error prevention by providing information on indications, dosage calculations, potential interactions, and relevant dosage adjustments. Clinicians must be present during the administration of parenteral iron to patients. Furthermore, nurses should diligently monitor patients following iron dextran administration to promptly identify any adverse drug reactions.</p>
        <p>Most infusion reactions are mild and resolve by interrupting the infusion. In cases where pharmacological intervention is necessary, the interprofessional healthcare team may opt for IV fluids, corticosteroids, and IM epinephrine, depending on the reaction's severity.<xref ref-type="bibr" rid="article-23768.r45">[45]</xref><xref ref-type="bibr" rid="article-23768.r27">[27]</xref>&#x000a0;Antihistamines are not recommended in this context.<xref ref-type="bibr" rid="article-23768.r27">[27]</xref> By ensuring proper training, fostering open interprofessional communication, and promoting cooperation, healthcare teams enhance their ability to provide quality patient-centered care and ultimately improve overall patient outcomes.</p>
      </sec>
      <sec id="article-23768.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23768&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23768">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/23768/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=23768">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-23768.s11">
        <title>References</title>
        <ref id="article-23768.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Johnson</surname>
                <given-names>CS</given-names>
              </name>
            </person-group>
            <article-title>Intravenous iron-dextran in the treatment of iron deficient anemia.</article-title>
            <source>J Natl Med Assoc</source>
            <year>1979</year>
            <month>Nov</month>
            <volume>71</volume>
            <issue>11</issue>
            <fpage>1101</fpage>
            <page-range>1101-5</page-range>
            <pub-id pub-id-type="pmid">529311</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23768.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Burns</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Mascioli</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Bistrian</surname>
                <given-names>BR</given-names>
              </name>
            </person-group>
            <article-title>Parenteral iron dextran therapy: a review.</article-title>
            <source>Nutrition</source>
            <year>1995</year>
            <season>Mar-Apr</season>
            <volume>11</volume>
            <issue>2</issue>
            <fpage>163</fpage>
            <page-range>163-8</page-range>
            <pub-id pub-id-type="pmid">7647482</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23768.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Auerbach</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ballard</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Glaspy</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Clinical update: intravenous iron for anaemia.</article-title>
            <source>Lancet</source>
            <year>2007</year>
            <month>May</month>
            <day>05</day>
            <volume>369</volume>
            <issue>9572</issue>
            <fpage>1502</fpage>
            <page-range>1502-1504</page-range>
            <pub-id pub-id-type="pmid">17482969</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23768.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schaefer</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Meindl</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Wagner</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tilg</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zoller</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Intravenous iron supplementation therapy.</article-title>
            <source>Mol Aspects Med</source>
            <year>2020</year>
            <month>Oct</month>
            <volume>75</volume>
            <fpage>100862</fpage>
            <pub-id pub-id-type="pmid">32444112</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23768.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Allen</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Picchietti</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Auerbach</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>YW</given-names>
              </name>
              <name>
                <surname>Connor</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Earley</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Garcia-Borreguero</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kotagal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Manconi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ondo</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Ulfberg</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Winkelman</surname>
                <given-names>JW</given-names>
              </name>
              <collab>International Restless Legs Syndrome Study Group (IRLSSG)</collab>
            </person-group>
            <article-title>Evidence-based and consensus clinical practice guidelines for the iron treatment of restless legs syndrome/Willis-Ekbom disease in adults and children: an IRLSSG task force report.</article-title>
            <source>Sleep Med</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>41</volume>
            <fpage>27</fpage>
            <page-range>27-44</page-range>
            <pub-id pub-id-type="pmid">29425576</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23768.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Silverstein</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Rodgers</surname>
                <given-names>GM</given-names>
              </name>
            </person-group>
            <article-title>Parenteral iron therapy options.</article-title>
            <source>Am J Hematol</source>
            <year>2004</year>
            <month>May</month>
            <volume>76</volume>
            <issue>1</issue>
            <fpage>74</fpage>
            <page-range>74-8</page-range>
            <pub-id pub-id-type="pmid">15114602</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23768.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ganz</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Macrophages and Iron Metabolism.</article-title>
            <source>Microbiol Spectr</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>4</volume>
            <issue>5</issue>
            <pub-id pub-id-type="pmid">27763254</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23768.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Can&#x000e7;ado</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Mu&#x000f1;oz</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Intravenous iron therapy: how far have we come?</article-title>
            <source>Rev Bras Hematol Hemoter</source>
            <year>2011</year>
            <volume>33</volume>
            <issue>6</issue>
            <fpage>461</fpage>
            <page-range>461-9</page-range>
            <pub-id pub-id-type="pmid">23049364</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23768.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gomme</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>McCann</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Bertolini</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Transferrin: structure, function and potential therapeutic actions.</article-title>
            <source>Drug Discov Today</source>
            <year>2005</year>
            <month>Feb</month>
            <day>15</day>
            <volume>10</volume>
            <issue>4</issue>
            <fpage>267</fpage>
            <page-range>267-73</page-range>
            <pub-id pub-id-type="pmid">15708745</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23768.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Knutson</surname>
                <given-names>MD</given-names>
              </name>
            </person-group>
            <article-title>Iron transport proteins: Gateways of cellular and systemic iron homeostasis.</article-title>
            <source>J Biol Chem</source>
            <year>2017</year>
            <month>Aug</month>
            <day>04</day>
            <volume>292</volume>
            <issue>31</issue>
            <fpage>12735</fpage>
            <page-range>12735-12743</page-range>
            <pub-id pub-id-type="pmid">28615441</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23768.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ascenzi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bocedi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Visca</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Altruda</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Tolosano</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Beringhelli</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Fasano</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Hemoglobin and heme scavenging.</article-title>
            <source>IUBMB Life</source>
            <year>2005</year>
            <month>Nov</month>
            <volume>57</volume>
            <issue>11</issue>
            <fpage>749</fpage>
            <page-range>749-59</page-range>
            <pub-id pub-id-type="pmid">16511968</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23768.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Noguchi</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Rogers</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Teng</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jia</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Survival and proliferative roles of erythropoietin beyond the erythroid lineage.</article-title>
            <source>Expert Rev Mol Med</source>
            <year>2008</year>
            <month>Dec</month>
            <day>01</day>
            <volume>10</volume>
            <fpage>e36</fpage>
            <pub-id pub-id-type="pmid">19040789</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23768.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Geisser</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Burckhardt</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>The pharmacokinetics and pharmacodynamics of iron preparations.</article-title>
            <source>Pharmaceutics</source>
            <year>2011</year>
            <month>Jan</month>
            <day>04</day>
            <volume>3</volume>
            <issue>1</issue>
            <fpage>12</fpage>
            <page-range>12-33</page-range>
            <pub-id pub-id-type="pmid">24310424</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23768.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Funk</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Fl&#x000fc;hmann</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Barton</surname>
                <given-names>AE</given-names>
              </name>
            </person-group>
            <article-title>Criticality of Surface Characteristics of Intravenous Iron-Carbohydrate Nanoparticle Complexes: Implications for Pharmacokinetics and Pharmacodynamics.</article-title>
            <source>Int J Mol Sci</source>
            <year>2022</year>
            <month>Feb</month>
            <day>15</day>
            <volume>23</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">35216261</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23768.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kohgo</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ikuta</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ohtake</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Torimoto</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kato</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Body iron metabolism and pathophysiology of iron overload.</article-title>
            <source>Int J Hematol</source>
            <year>2008</year>
            <month>Jul</month>
            <volume>88</volume>
            <issue>1</issue>
            <fpage>7</fpage>
            <page-range>7-15</page-range>
            <pub-id pub-id-type="pmid">18594779</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23768.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Auerbach</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ballard</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Clinical use of intravenous iron: administration, efficacy, and safety.</article-title>
            <source>Hematology Am Soc Hematol Educ Program</source>
            <year>2010</year>
            <volume>2010</volume>
            <fpage>338</fpage>
            <page-range>338-47</page-range>
            <pub-id pub-id-type="pmid">21239816</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23768.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Danielson</surname>
                <given-names>BG</given-names>
              </name>
            </person-group>
            <article-title>Structure, chemistry, and pharmacokinetics of intravenous iron agents.</article-title>
            <source>J Am Soc Nephrol</source>
            <year>2004</year>
            <month>Dec</month>
            <volume>15 Suppl 2</volume>
            <fpage>S93</fpage>
            <page-range>S93-8</page-range>
            <pub-id pub-id-type="pmid">15585603</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23768.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <article-title>IV. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: update 2000.</article-title>
            <source>Am J Kidney Dis</source>
            <year>2001</year>
            <month>Jan</month>
            <volume>37</volume>
            <issue>1 Suppl 1</issue>
            <fpage>S182</fpage>
            <page-range>S182-238</page-range>
            <pub-id pub-id-type="pmid">11229970</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23768.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <article-title>Anemia in Pregnancy: ACOG Practice Bulletin, Number 233.</article-title>
            <source>Obstet Gynecol</source>
            <year>2021</year>
            <month>Aug</month>
            <day>01</day>
            <volume>138</volume>
            <issue>2</issue>
            <fpage>e55</fpage>
            <page-range>e55-e64</page-range>
            <pub-id pub-id-type="pmid">34293770</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23768.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lewkowitz</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Tuuli</surname>
                <given-names>MG</given-names>
              </name>
            </person-group>
            <article-title>Identifying and treating iron deficiency anemia in pregnancy.</article-title>
            <source>Hematology Am Soc Hematol Educ Program</source>
            <year>2023</year>
            <month>Dec</month>
            <day>08</day>
            <volume>2023</volume>
            <issue>1</issue>
            <fpage>223</fpage>
            <page-range>223-228</page-range>
            <pub-id pub-id-type="pmid">38066889</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23768.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chertow</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Mason</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Vaage-Nilsen</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Ahlm&#x000e9;n</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Update on adverse drug events associated with parenteral iron.</article-title>
            <source>Nephrol Dial Transplant</source>
            <year>2006</year>
            <month>Feb</month>
            <volume>21</volume>
            <issue>2</issue>
            <fpage>378</fpage>
            <page-range>378-82</page-range>
            <pub-id pub-id-type="pmid">16286429</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23768.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fishbane</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kowalski</surname>
                <given-names>EA</given-names>
              </name>
            </person-group>
            <article-title>The comparative safety of intravenous iron dextran, iron saccharate, and sodium ferric gluconate.</article-title>
            <source>Semin Dial</source>
            <year>2000</year>
            <season>Nov-Dec</season>
            <volume>13</volume>
            <issue>6</issue>
            <fpage>381</fpage>
            <page-range>381-4</page-range>
            <pub-id pub-id-type="pmid">11130261</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23768.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Litton</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Xiao</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>KM</given-names>
              </name>
            </person-group>
            <article-title>Safety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: systematic review and meta-analysis of randomised clinical trials.</article-title>
            <source>BMJ</source>
            <year>2013</year>
            <month>Aug</month>
            <day>15</day>
            <volume>347</volume>
            <fpage>f4822</fpage>
            <pub-id pub-id-type="pmid">23950195</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23768.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>DeLoughery</surname>
                <given-names>TG</given-names>
              </name>
            </person-group>
            <article-title>Safety of Oral and Intravenous Iron.</article-title>
            <source>Acta Haematol</source>
            <year>2019</year>
            <volume>142</volume>
            <issue>1</issue>
            <fpage>8</fpage>
            <page-range>8-12</page-range>
            <pub-id pub-id-type="pmid">30970354</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23768.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Van Doren</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Auerbach</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>IV iron formulations and use in adults.</article-title>
            <source>Hematology Am Soc Hematol Educ Program</source>
            <year>2023</year>
            <month>Dec</month>
            <day>08</day>
            <volume>2023</volume>
            <issue>1</issue>
            <fpage>622</fpage>
            <page-range>622-629</page-range>
            <pub-id pub-id-type="pmid">38066930</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23768.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fletes</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lazarus</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Gage</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chertow</surname>
                <given-names>GM</given-names>
              </name>
            </person-group>
            <article-title>Suspected iron dextran-related adverse drug events in hemodialysis patients.</article-title>
            <source>Am J Kidney Dis</source>
            <year>2001</year>
            <month>Apr</month>
            <volume>37</volume>
            <issue>4</issue>
            <fpage>743</fpage>
            <page-range>743-9</page-range>
            <pub-id pub-id-type="pmid">11273874</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23768.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Szebeni</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fishbane</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hedenus</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Howaldt</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Locatelli</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Patni</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rampton</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Weiss</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Folkersen</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Hypersensitivity to intravenous iron: classification, terminology, mechanisms and management.</article-title>
            <source>Br J Pharmacol</source>
            <year>2015</year>
            <month>Nov</month>
            <volume>172</volume>
            <issue>21</issue>
            <fpage>5025</fpage>
            <page-range>5025-36</page-range>
            <pub-id pub-id-type="pmid">26265306</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23768.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Auerbach</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Al Talib</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Low-molecular weight iron dextran and iron sucrose have similar comparative safety profiles in chronic kidney disease.</article-title>
            <source>Kidney Int</source>
            <year>2008</year>
            <month>Mar</month>
            <volume>73</volume>
            <issue>5</issue>
            <fpage>528</fpage>
            <page-range>528-30</page-range>
            <pub-id pub-id-type="pmid">18274543</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23768.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Akhuemonkhan</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Parian</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Carson</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Hutfless</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Adverse Reactions After Intravenous Iron Infusion Among Inflammatory Bowel Disease Patients in the United States, 2010-2014.</article-title>
            <source>Inflamm Bowel Dis</source>
            <year>2018</year>
            <month>Jul</month>
            <day>12</day>
            <volume>24</volume>
            <issue>8</issue>
            <fpage>1801</fpage>
            <page-range>1801-1807</page-range>
            <pub-id pub-id-type="pmid">29669068</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23768.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yessayan</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sandhu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Besarab</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yessayan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Frinak</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zasuwa</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Yee</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Intravenous iron dextran as a component of anemia management in chronic kidney disease: a report of safety and efficacy.</article-title>
            <source>Int J Nephrol</source>
            <year>2013</year>
            <volume>2013</volume>
            <fpage>703038</fpage>
            <pub-id pub-id-type="pmid">23573422</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23768.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Avni</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Bieber</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Grossman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Green</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Leibovici</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gafter-Gvili</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>The safety of intravenous iron preparations: systematic review and meta-analysis.</article-title>
            <source>Mayo Clin Proc</source>
            <year>2015</year>
            <month>Jan</month>
            <volume>90</volume>
            <issue>1</issue>
            <fpage>12</fpage>
            <page-range>12-23</page-range>
            <pub-id pub-id-type="pmid">25572192</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23768.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hougen</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Collister</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bourrier</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ferguson</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hochheim</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Komenda</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rigatto</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tangri</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Safety of Intravenous Iron in Dialysis: A Systematic Review and Meta-Analysis.</article-title>
            <source>Clin J Am Soc Nephrol</source>
            <year>2018</year>
            <month>Mar</month>
            <day>07</day>
            <volume>13</volume>
            <issue>3</issue>
            <fpage>457</fpage>
            <page-range>457-467</page-range>
            <pub-id pub-id-type="pmid">29463597</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23768.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rolla</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bucca</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Brussino</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Systemic reactions to intravenous iron therapy in patients receiving angiotensin converting enzyme inhibitor.</article-title>
            <source>J Allergy Clin Immunol</source>
            <year>1994</year>
            <month>Jun</month>
            <volume>93</volume>
            <issue>6</issue>
            <fpage>1074</fpage>
            <page-range>1074-5</page-range>
            <pub-id pub-id-type="pmid">8006314</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23768.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Del Vecchio</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Longhi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Locatelli</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Safety concerns about intravenous iron therapy in patients with chronic kidney disease.</article-title>
            <source>Clin Kidney J</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>9</volume>
            <issue>2</issue>
            <fpage>260</fpage>
            <page-range>260-7</page-range>
            <pub-id pub-id-type="pmid">26985378</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23768.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shah</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Donovan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Seeley</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dickson</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Palmer</surname>
                <given-names>AJR</given-names>
              </name>
              <name>
                <surname>Doree</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Brunskill</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Reid</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Acheson</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Sugavanam</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Litton</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Stanworth</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Risk of Infection Associated With Administration of Intravenous Iron: A Systematic Review and Meta-analysis.</article-title>
            <source>JAMA Netw Open</source>
            <year>2021</year>
            <month>Nov</month>
            <day>01</day>
            <volume>4</volume>
            <issue>11</issue>
            <fpage>e2133935</fpage>
            <pub-id pub-id-type="pmid">34767026</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23768.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rampton</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Folkersen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fishbane</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hedenus</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Howaldt</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Locatelli</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Patni</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Szebeni</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Weiss</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management.</article-title>
            <source>Haematologica</source>
            <year>2014</year>
            <month>Nov</month>
            <volume>99</volume>
            <issue>11</issue>
            <fpage>1671</fpage>
            <page-range>1671-6</page-range>
            <pub-id pub-id-type="pmid">25420283</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23768.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lim</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Afif</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Knowles</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Mothersill</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Nistor</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Rehman</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Xenodemetropoulos</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Canadian expert consensus: management of hypersensitivity reactions to intravenous iron in adults.</article-title>
            <source>Vox Sang</source>
            <year>2019</year>
            <month>May</month>
            <volume>114</volume>
            <issue>4</issue>
            <fpage>363</fpage>
            <page-range>363-373</page-range>
            <pub-id pub-id-type="pmid">30937914</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23768.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gelaw</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Woldu</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Melku</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>The Role of Reticulocyte Hemoglobin Content for Diagnosis of Iron Deficiency and Iron Deficiency Anemia, and Monitoring of Iron Therapy: a Literature Review.</article-title>
            <source>Clin Lab</source>
            <year>2019</year>
            <month>Dec</month>
            <day>01</day>
            <volume>65</volume>
            <issue>12</issue>
            <pub-id pub-id-type="pmid">31850722</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23768.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Elsayed</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Sharif</surname>
                <given-names>MU</given-names>
              </name>
              <name>
                <surname>Stack</surname>
                <given-names>AG</given-names>
              </name>
            </person-group>
            <article-title>Transferrin Saturation: A Body Iron Biomarker.</article-title>
            <source>Adv Clin Chem</source>
            <year>2016</year>
            <volume>75</volume>
            <fpage>71</fpage>
            <page-range>71-97</page-range>
            <pub-id pub-id-type="pmid">27346617</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23768.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gattermann</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Muckenthaler</surname>
                <given-names>MU</given-names>
              </name>
              <name>
                <surname>Kulozik</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Metzgeroth</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hastka</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>The Evaluation of Iron Deficiency and Iron Overload.</article-title>
            <source>Dtsch Arztebl Int</source>
            <year>2021</year>
            <month>Dec</month>
            <day>10</day>
            <volume>118</volume>
            <issue>49</issue>
            <fpage>847</fpage>
            <page-range>847-856</page-range>
            <pub-id pub-id-type="pmid">34755596</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23768.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bateman</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>Eagling</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Sandilands</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Jackson</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Crawford</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hawkins</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cheung</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Cooper</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bradberry</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>SHL</given-names>
              </name>
              <name>
                <surname>Eddleston</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Iron overdose epidemiology, clinical features and iron concentration-effect relationships: the UK experience 2008-2017.</article-title>
            <source>Clin Toxicol (Phila)</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>56</volume>
            <issue>11</issue>
            <fpage>1098</fpage>
            <page-range>1098-1106</page-range>
            <pub-id pub-id-type="pmid">29587543</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23768.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rottembourg</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rostoker</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>[Use of intravenous iron supplementation in chronic kidney disease: Interests, limits, and recommendations for a better practice].</article-title>
            <source>Nephrol Ther</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>11</volume>
            <issue>7</issue>
            <fpage>531</fpage>
            <page-range>531-42</page-range>
            <pub-id pub-id-type="pmid">26498106</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23768.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Polin</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Coriat</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Perkins</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Dhooge</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Abitbol</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Leblanc</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Prat</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Chaussade</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Iron deficiency: from diagnosis to treatment.</article-title>
            <source>Dig Liver Dis</source>
            <year>2013</year>
            <month>Oct</month>
            <volume>45</volume>
            <issue>10</issue>
            <fpage>803</fpage>
            <page-range>803-9</page-range>
            <pub-id pub-id-type="pmid">23582772</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23768.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Entezari</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Haghi</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Norouzkhani</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sahebnazar</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Vosoughian</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Akbarzadeh</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Islampanah</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Naghsh</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Abbasalizadeh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Deravi</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Iron Chelators in Treatment of Iron Overload.</article-title>
            <source>J Toxicol</source>
            <year>2022</year>
            <volume>2022</volume>
            <fpage>4911205</fpage>
            <pub-id pub-id-type="pmid">35571382</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23768.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Simons</surname>
                <given-names>FE</given-names>
              </name>
              <name>
                <surname>Ardusso</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Bil&#x000f2;</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>El-Gamal</surname>
                <given-names>YM</given-names>
              </name>
              <name>
                <surname>Ledford</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Ring</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sanchez-Borges</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Senna</surname>
                <given-names>GE</given-names>
              </name>
              <name>
                <surname>Sheikh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Thong</surname>
                <given-names>BY</given-names>
              </name>
              <collab>World Allergy Organization</collab>
            </person-group>
            <article-title>World allergy organization guidelines for the assessment and management of anaphylaxis.</article-title>
            <source>World Allergy Organ J</source>
            <year>2011</year>
            <month>Feb</month>
            <volume>4</volume>
            <issue>2</issue>
            <fpage>13</fpage>
            <page-range>13-37</page-range>
            <pub-id pub-id-type="pmid">23268454</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
